Quarter
Charts

CVS HEALTH CORPORATION

CVS

CIK 0000064803 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$105.69B
↑+8.2% +$7.98Bvs FY2024 (Q4)
Operating Income
$2.11B
↓-10.8% -$256Mvs FY2024 (Q4)
Net Income
$1.35B
↓-17.6% -$290Mvs FY2024 (Q4)
Gross Profit
$46.63B
↑+9.9% +$4.19Bvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
41/100
  • Profitability
    0ROIC 5.0% (10% = solid, 20%+ = moat)
  • Liquidity
    17Current Ratio 0.84 (above 1.5 = solid)
  • Leverage
    50D/E 1.01 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 1.59x (1.0+ = capital-efficient)
  • Growth
    44Revenue YoY +8.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    32Op Margin 2.0% · trend -1.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CVS's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -16.6%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$85.75
Total enterprise IV
$108.99B
Diluted shares
1.27B
Terminal PV
$76.80B (70% of total)
Year-5 FCF
$9.05B
YearProjected FCFDiscounted PV
+1$8.04B$7.31B
+2$8.28B$6.84B
+3$8.53B$6.41B
+4$8.79B$6.00B
+5$9.05B$5.62B
Terminal$123.69B$76.80B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2.83B
investment in PP&E
Dividends paid (TTM)
$3.40B
cash returned to holders
Stock buybacks (TTM)
$0
share count reduction
Stock-based comp (TTM)
$535M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$253.54B
everything owned
Total liabilities
$178.16B
everything owed
Stockholders' equity
$75.21B
shareholder claim
Net debt
$55.03B
LT debt minus cash

Recent performance · 74 quarters

Revenue↑+8.2% +$7.98B
$105.69B
Net Income↑+79.0% +$1.30B
$2.94B
Free Cash Flow↑+138.6% +$1.51B
$2.61B
Operating Margin↓-0.4pts
2.0%

Drill down

CVS Sankey

See CVS HEALTH CORPORATION's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

CVS Charts

74 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

CVS Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics